Sort   by:  
 Page size 
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14640 | MetaboLights

CD8+ T cells detect and kill virally infected or cancerous cells. When activated from their naïve state, T cells undergo a complex transition, including major metabolic reprogramming. Detailed resolution of metabolic dynamics of a wide range of metabolites is needed to advance the field of immuno...

2021-06-02 | MTBLS2145 | MetaboLights
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14634 | MetaboLights
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14641 | MetaboLights

Butyrate, one of the most abundant microbial-derived metabolites in the gut, is important in regulating intestinal homeostasis. In this study, we used untargeted global metabolomics to landscape the intestinal epithelial cellular metabolites changed by butyrate treatment.

2026-06-26 | MTBLS14301 | MetaboLights

Paraoxonase-1 (PON1) is specifically expressed in the liver and has crucial effects on various liver diseases. The functions and mechanisms underlying of PON1 in hepatocellular carcinoma (HCC) remain obscure. Here, we show that PON1 acts as a metabolic regulator to mitigate regulatory T (Treg) ce...

2025-09-07 | MTBLS12950 | MetaboLights

Background: The objective response rate of anti-programmed death receptor 1 (PD-1) immunotherapy in hepatocellular carcinoma (HCC) remains limited. The tumor immunosuppressive microenvironment mediated by regulatory T cells (Tregs) is a key bottleneck. The traditional Chinese medicine (TCM) compo...

2025-12-05 | MTBLS13458 | MetaboLights

Small cell lung cancer (SCLC) exhibits profound immunometabolic suppression that impairs antigen presentation and constrains immunotherapy efficacy. Through integrated multi-omics analyses of primary human SCLC tumors, we identified midkine (MDK) as a dominant tumor-secreted driver of immune evas...

2026-03-23 | MTBLS14116 | MetaboLights

BACKGROUND: The protozoan parasite Toxoplasma gondii infects and alters the neurotransmission in cerebral cortex and other brain regions, leading to neurobehavioral and neuropathologic changes in humans and animals. However, the molecules that contribute to these changes remain l...

2020-04-23 | MTBLS770 | MetaboLights

Osteocytes could release some small molecules (≤ 1 kDa) through gap junctions and hemichannels to extracellular environment, such as prostaglandin E2 (PGE2), nitric oxide (NO) and adenosine triphosphate (ATP), which play key roles in transferring signals between bone cells and other tissue cells....

2021-04-14 | MTBLS2358 | MetaboLights
Sort   by:  
 Page size